ArticleFrontiers in medicine2025
Global trends and inequalities in eye cancer burden: a comprehensive analysis based on the global burden of disease study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Histopathological spectrum of ocular masses in a tertiary eye center in Northern China: a 12-year retrospective analysis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Eye cancer is a significant threat to vision and survival because of its location, diagnostic challenges, and aggressive nature. However, its global epidemiology, especially regarding differences across countries, age groups, and sex, is not well-studied. Methods: This study analyzed data from the Global Burden of Disease Study 2021 to evaluate trends in eye cancer, focusing on incidence, prevalence, mortality, and disability-adjusted life years (DALYs) across 204 countries from 1990 to 2021. Age-standardized rates and estimated annual percentage changes were used to assess trends over time. Disparities were examined by sociodemographic index (SDI), sex, and age, with concentration and slope index analyses assessing development-and sex-related inequalities. Results: From 1990 to 2021, the global burden of eye cancer showed an overall increase in incidence and prevalence, with notable geographic and sociodemographic variations. Sociodemographic analysis revealed persistent inequalities, with higher detection-related prevalence and incidence in developed regions and greater mortality and disability in less developed areas. Age-specific prevalence demonstrated a rightward shift, with older populations, particularly those aged ≥65 years, carrying the largest burden. Sex disparities were also evident, as men generally exhibited higher incidence and prevalence rates, while women in low-SDI regions faced a disproportionate share of mortality and DALY burden. Conclusion: This study highlights significant global disparities in eye cancer, influenced by sociodemographic factors, sex, and age. Urgent investment in diagnostic infrastructure, equitable care, and sex-sensitive measures is essential to reduce preventable vision loss and cancer deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.